A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). [electronic resource]
Producer: 20170726Description: 92-100 p. digitalISSN:- 1873-5835
- Adult
- Aged
- Aged, 80 and over
- Cytarabine -- adverse effects
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Enzyme Inhibitors -- pharmacology
- Female
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
- Proto-Oncogene Proteins c-mdm2 -- antagonists & inhibitors
- Salvage Therapy
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.